SGT-003
Gene Therapy Target: dystrophin, microdystrophin
Solid Biosciences
Most recent annual filing: 2026-03-15
- SGT-003 guidance updateMid-2026SGT-003 guidance update, Mid-2026, notable
- SGT-212 interim2H 2026SGT-212 interim, 2H 2026, notable
- SGT-501 interim2H 2026SGT-501 interim, 2H 2026, notable
- SGT-501 Ph1 start2H 2026SGT-501 Ph1 start, 2H 2026, routine
- IMPACT DUCHENNE Phase 3 corporate2H 2026IMPACT DUCHENNE Phase 3 corporate, 2H 2026, routine
- SGT-003 FDA approvallate 4Q 2026SGT-003 FDA approval, late 4Q 2026, thesis-defining
- SGT-501 Ph1 readout1H 2027SGT-501 Ph1 readout, 1H 2027, notable
- SGT-212 Ph1 readout1Q 2027SGT-212 Ph1 readout, 1Q 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
SGT-212
Gene Therapy Target: frataxin, FXN
SGT-501
Gene Therapy Target: CASQ2, RYR2
SGT-601
Gene Therapy Target: TNNT2, cardiac troponin T
SGT-401
Gene Therapy Target: BAG3
SGT-701
Gene Therapy Target: RBM20
Technology platforms
POLARIS-101
Rationally designed next-generation AAV capsid (AAV-SLB101) engineered for systemic delivery with improved transduction in the presence of neutralizing antibodies; applications in neuromuscular and cardiac gene therapy including Duchenne Muscular Dystrophy, dilated cardiomyopathy, and FSHD
Targets: integrin receptors
Novel Capsid and Promoter Libraries
Scalable high-throughput platform for next-generation capsid design targeting cardiac and neuromuscular diseases; leverages deep capsid structure knowledge, peptide insertions, generative AI, and affinity maturation to improve biodistribution and expression. Capsid selection from first library anticipated 2H 2026.
Mayo Clinic Cardiac Gene Therapy Collaboration · Mayo Foundation for Medical Education and Research
Collaboration platform with Mayo Foundation for Medical Education and Research covering six undisclosed preclinical cardiac gene therapy programs; Mayo conducts IND-enabling studies, Solid retains rights to select programs for clinical development and exclusive commercialization.
POLARIS-101 · Addgene
Next-generation, muscle-tropic AAV capsid (formerly AAV-SLB101) designed to target integrin receptors, with enhanced cardiac and skeletal muscle transduction and decreased liver targeting; used in SGT-003 and licensed broadly to corporations, institutions, and academic labs.
Biotech Distilled coverage (5)
- 2026-08-07 UPDATE: Solid Biosciences (SLDB) - The Binary Slips to Q4, and the ATM Gets a Bigger Barrel 🔒 Paid
- 2026-06-25 UPDATE: Solid Biosciences (SLDB) - RA Capital Doubles Down, and the ATM Quietly Fires 🔒 Paid
- 2026-05-12 UPDATE: Solid Biosciences (SLDB) - The Dilution Gap Closes, the Phase 3 Clock Starts 🔒 Paid
- 2026-03-22 UPDATE: Solid Biosciences (SLDB) - The S-3 Dilution Playbook, a New 13D, and the Burn Rate Reality 🔒 Paid
- 2026-03-12 Solid Biosciences (SLDB) - Scientific Deep Dive for SGT-003 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.